Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | BMP1 | P13497 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5437700 | 0.78 | MEN1 (0.45) | KMT2AMEN1HSD11B1CCR1BMP1 | |
| SCHEMBL5434633 | 0.76 | TRPV4 (0.42) | KMT2ACCR1BMP1ADAM17TRPV4 | |
| SCHEMBL4142306 | 0.75 | BMP1 (0.37) | KMT2AMEN1CCR1BMP1ADAM17 | |
| SCHEMBL5439595 | 0.72 | CNR2 (0.37) | HSD11B1EPHX2 | |
| SCHEMBL4147711 | 0.72 | TRPV4 (0.39) | KMT2AMEN1CCR1TRPV4KCNA5 | |
| SCHEMBL5429673 | 0.72 | CNR2 (0.36) | HSD11B1EPHX2 | |
| SCHEMBL4140789 | 0.71 | TRPV4 (0.38) | KMT2AMEN1CCR1TRPV4 | |
| SCHEMBL5429196 | 0.71 | CCR1 (0.40) | HSD11B1CCR1BMP1ADAM17TRPV4 | |
| SCHEMBL4139936 | 0.70 | CNR2 (0.37) | HSD11B1EPHX2 | |
| SCHEMBL4140796 | 0.70 | CNR2 (0.36) | HSD11B1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | claimed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | TRPV4, TRPC4, TRPV1 | KMT2A 3582/4885MEN1 1683/4885HSD11B1 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.